Most autoantigens implicated in multiple sclerosis (MS) are expressed not only in the central nervous system (CNS) but also in the thymus and the periphery. Nevertheless, these autoantigens might induce a strong autoimmune response leading to severe destruction within the CNS. To investigate the influence of a dominantly presented autoantigen on experimental autoimmune encephalomyelitis (EAE), we generated transgenic mice expressing the autoantigenic peptide MBP 1-10 covalently bound to the MHC class II molecule I-A u . These mice were crossed either with B10.PL or with TCR-transgenic Tg4 mice, specific for the transgenic peptide-MHC combination. In double transgenic mice we found strong thymic deletion and residual peripheral T cells were refractory to antigen stimulation in vitro.
Introduction
The common concept regarding organ-specific autoimmune diseases like multiple sclerosis (MS) implies that organspecific antigens are hidden from the naive immune repertoire due to lack of expression outside the organ and to the inability of naive T cells to trans-migrate into these organs. In this way the immune system would not be tolerant towards these hidden antigens but simply ignorant. It is thought that external triggers like viral or bacterial infections initiate the destructive immune response against autoantigens. Infections could either condition the organ and give access to formerly hidden antigens or could activate pre-existing autoantigen-specific naive T cells by molecular mimicry or bystander activation (1, 2) . In contrast to naive T cells, activated T cells efficiently trans-migrate into tissues, thereby initiating the autoimmune disease (3) . This view was strengthened by experiments with mice harboring TCR-transgenic T cells, which ignored their antigen expressed specifically in the pancreas until infected with viruses expressing this antigen, which ultimately lead to diabetes (4, 5) .
This concept of immunological ignorance was challenged by others, who showed that antigens expressed specifically in peripheral organs are indeed recognized by peripheral T cells but readily induce tolerance of the antigen-specific T cells (6) . In one system even very low levels of peripherally expressed antigen lead to tolerance induction (7) . It was later shown that this so-called ''peripheral tolerance mechanism'' was dependent on the continuous presence of the antigen (8) and was, in the case of liver-specific antigens, broken by IL-2, irradiation or by listeria infection (9) (10) (11) . These findings were supported by the concept of the danger theory from Matzinger (12) , which emphasizes that only antigens in the context of danger molecules like that seen during infections, now called pathogen-associated molecular patterns (PAMPs) (13) , lead to the mounting of a destructive (auto-) immune response.
For a long time the central nervous system (CNS) was seen as a special immune-privileged organ that is protected by the blood-brain barrier from the cellular and humoral immune system and that lacks the normal lymphatic drainage of other organs. By this means many of the CNS-specific antigens should be hidden for the immune repertoire (14, 15) .
Recently it was shown that in addition to activated T cells also naive T cells might migrate into the brain (16, 17) . It also became evident that most of the formerly so-called brainspecific antigens are also expressed either by other peripheral organs or by the thymus (18) (19) (20) (21) (22) (23) . These two facts contradict the idea of ''sequestered autoantigens''. As most of these antigens are expressed also in the thymus and/or in the periphery, they should induce central and/or peripheral tolerance mechanisms, respectively.
A possible explanation of CNS-autoimmune diseases is the existence of a balanced system between tolerance induction, on the one hand, and the precursor frequency and activation of autoreactive T cells, on the other. To investigate this hypothesis, we created transgenic mice that express the autoantigenic N-terminal MBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] peptide, covalently bound to the MHC class II molecule I-A u under the control of an MHC class II promoter. These mice dominantly present the antigen in the thymus and the periphery. We crossed two of these lines, with different expression levels of the transgene, with B10.PL or Tg4 mice transgenic for a TCR, which recognizes the latter peptide-MHC combination (24) . These mice allowed us to investigate the influence of T cell precursor frequency and autoantigen expression on experimental autoimmune encephalomyelitis (EAE) induction.
We show here that even under very strong tolerance-inducing conditions, where a myelin-autoantigen is dominantly presented in the thymus and in the periphery, some TCR-transgenic mice are susceptible to EAE after an extended induction period.
Methods

Mice
All mice were kept under specific pathogen-free conditions in the animal facilities of the German Cancer Research Centre. B10.PL mice were from Jackson Laboratories and DBA/2 and C57BL/6 strains were from in-house breeding or from WIGA (Hanover, Germany). TCR-transgenic Tg4 mice express the TCR of the T cell hybridoma 1934.4 (Va4 and Vb8.2) derived from an encephalitogenic CD4-positive Tcell clone (24, 25 (see below) on an I-A u -negative background were crossed with Tg4 mice, litters were tested for the transgenes, and F1-heterozygous animals were used for the assays.
Generation of transgenic MBP-IA u mice
We received from David Wraith the I-A u a and b cDNAs in the expression vectors pHbAPr-2-neo and pHbApr-2gpt, respectively. The Vector pDR51 with the human MHC class II DRb51 promoter was from Yoshinori Fukui. This promoter was described as vector for reliable and MHC class II-specific expression in several transgenic mouse systems (26, 27) . To have an intron in our transgene vectors, we exchanged the SV40-termination sequence of pDR51 by the SV40 splice poly(A) sequence derived via PCR (primer A, TAAGAATTCAAGCTTA-GATCTGATCTTTGTGAAGGAACC, and primer B, AATAAGCT-TGAATTCGGTACCCGGGGATCGATCCAGACAT) from the vector pBLCAT6. The PCR product was ligated into the HindIII and EcoRI sites of pDR51 to generate pDR51 splice.
b-chain construct
With a first PCR we introduced the C-terminal part of the DRb51 signal sequence, the MBP peptide and the restriction sites SacI, BglII, and HindIII into the I-A u -b cDNA. (primer C, TAAGAATTCGAGCTCCCCACTGGCTTTGGCTGGAGACTC-CGGCGCATCACAGAAGAGACCCTCACAGAGATCTGAAA-GGCATTTCTTGGTCCAG, and primer D, ATTGGATCCAAGC-TTTCACTGCAGGAGCCCTGCTGG). For the appropriate cleavage of the signal sequence we had to introduce the amino acid sequence GDS N-terminal to the MBP sequence. As a replacement of the natural acetylation we use a glycine residue between the GDS sequence and the MBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] sequence (see Fig. 1 and text) . With that PCR product we replaced the DRb51 cDNA of pDR51 splice via SacI and HindIII and created pDR-IA u b splice. With a second PCR we introduced the linker sequence and two BglII sites into the original I-A u cDNA (primer E, GCGGAATTCAGATCTGGAGGT-GGTGGATCCGGTGGAGGAGGGAGTGGCGGAGGTGGAA-GCGAAAGGCATTTCTTGGTCCAG, and primer F, ATTGGATC-CAGATTAAGCTTTCACTGCAGGAGCCCTGCTGG). This PCR product was cloned into the BglII sites of pDR-IA u b splice to get pDR-MBP-IA u b splice (Fig. 1) .
a-chain construct
For expression of the a chain we also used the DR51 promoter. As we did not want to introduce the GDS sequence N-terminal to the a chain for the proper cleavage of the human pDR51-signal sequence, we planned to replace the three C-terminal amino acid residues of the human signal sequence by the five C-terminal signal sequence residues from the mouse I-A k sequence. With PCR we introduced the five signal sequence residues and SacI and BglII sites into the I-A u a cDNA sequence (primer G, TAAGAATTCGAGCTCCCCACTCAGCCTCTGCG-GAGGTGAAGACGACATTGAGGCCGACCATGTAGGC, and primer H, TAAGGATCCAGATCTGAATTCCAAGGGTGTGTG). The PCR product was cloned into the SacI and BglII sites of pDR-IA u b splice to get pDR-IA u a splice (Fig. 1) . Both pDR-IA Peptides N-terminal-acetylated MBP 1-10 peptide Ac-ASQKRPSQRS (Ac1-10) and its analog with higher affinity to the I-A u molecule Ac-ASQYRPSQRS (Ac1-10 (4Y)) were synthesized in-house using standard Fmoc chemistry and were HPLC purified.
FACS staining and analysis
Staining was performed at 4°C in Dulbecco's modified PBS supplemented with 3% FCS, 0.45% glucose and 0.01% sodium azide. For most stainings 2-5 3 10 5 cells from single-cell suspensions were used and were pre-treated with anti-CD16 and anti-CD32 antibodies (Fc-block from BDPharmingen) to reduce unspecific staining. Antibodies from BD-Pharmingen were as follows: anti-CD4 PE-labeled GK1.5 clone; anti-CD8a FITC-, biotin-or PE-labeled (53-6.7); anti-CD45R (B220) FITC-, biotin-or PE-labeled; anti-CD62L biotin-labeled (MEL-14); anti-CD69 biotin-labeled (H1.2F3); anti-CD25 biotin-labeled (7D4). Antibodies from GIBCO: anti-CD4 Red613-labeled (H129.19) and anti-CD8a Red613-labeled (53-6.7). The anti-Vb8-antibody F23.1 (28) and the anti-I-Ab u antibodies MKS4 (29) and 10-2-16 (30) were labeled in our laboratory with biotin (Biotin-X-NHS, Calbiochem) and FITC (Sigma), respectively. To exclude dead cells, cells in the live gate were analyzed and if possible stained with propidium iodide (1 lg ml ÿ1 ); 5000-10 000 cells were analyzed by flow cytometry (FACScan; BD).
Bone marrow-derived dendritic cells
Bone marrow stem cells were prepared and differentiated to bone marrow-derived dendritic cells (BMDCs) according to a protocol from Lutz et al. (31) . The bone marrow cells were differentiated for 9 days in granulocyte macrophage colonystimulating factor (GM-CSF) containing medium. The medium was composed of RPMI supplemented with 10% FCS (Seromed), 2 mM L-glutamine, 100 U ml ÿ1 penicillin/streptomycin, 0.1 mM 2-mercaptoethanol and 10% of GM-CSF containing supernatant of F1/16 cells. For activation, LPS (1 lg ml ÿ1 ) was added to the cultures and 24 h later, non-adherent, activated BMDCs were used for FACS staining or T cell proliferation assays. For staining of the transgenic MHC class II on BMDCs the anti-I-A u antibody 10-2-16-bio with streptavidin-PE (SA-PE) was used. 
EAE induction and scoring
Active EAE was induced according to protocols from Liu and Wraith (32) and Coligan (33) . To incomplete freunds adjuvant (IFA) heat-killed Mycobacterium tuberculosis (strain H37 RA; Difco) was added to a concentration of 4 mg ml ÿ1 and solubilized via ultrasound. The autoantigenic MBP peptide Ac1-10 at 4 mg ml ÿ1 in DPBS was emulsified 1:1 with the IFA/M. tuberculosis mixture. Each mice was injected with 100 ll of the emulsion (according to 200 lg peptide) subcutaneous at the base of the tail. At day 1 and 3 after immunization each mouse was intraperitonealy injected with 200 ng pertussis toxin (Calbiochem) in 500 ll DPBS. The clinical symptoms were scored according to Coligan (33)-score: 0, normal; 1, limp tail or hind limb weakness; 2, limp tail and hind limb weakness; 3, partial hind limp paralysis; 4, complete hind limb paralysis; 5, dead or moribund, killed by investigator.
Results
Generation of transgenic mice
We wanted to investigate the influence of an autoantigenic peptide, permanently presented by professional antigenpresenting cells (APCs), on the induction of EAE. Therefore we generated transgenic mice, which dominantly present the autoantigenic peptide MBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] in the context of the murine MHC class II molecule I-A u . To acquire reliable autoantigen presentation, we used a system previously used by other groups to investigate the role of specific peptides in thymic selection (27, 34) . We fused the MBP peptide 1-10 and a glycine-serine linker N-terminal to the I-A u b chain (Fig. 1) . The natural N-terminus of the MBP peptide is acetylated and this post-translational modification was shown to be important for binding to I-A u (35, 36) . Since it was shown to be a good substitution for the acetylation (35-37), we chose the stericsimilar glycine as a replacement. We also placed the first three amino acid residues of the I-A u b chain N-terminal to the MBP peptide to allow proper cleavage of the DRb51 signal sequence (27) (Fig. 1) . Experiments with the hybridoma cell line 1934.4, specific for I-A u and MBP Ac1-9, showed that such an N-terminal-extended peptide stimulates the hybridoma equally as well as the normal acetylated peptide (data not shown). Since we wanted the MBP-IA u fusion product to be expressed in the natural context of MHC class II expression, we chose the human DRb51 promoter for the IA u a and the MBP-IA 
MHC class II-specific expression of the transgenes
To analyze expression of the transgenes we crossed both founder lines on an H-2 b background. We stained lymphocytes of these mice with antibodies against I-A u and compared these stainings to lymphocytes from B10.PL (H-2 u ) mice (Fig. 2) . We found typical MHC class II-specific expression on B cells in the LNs (Fig. 2A) (Fig. 2B) . We found high expression of the transgenic MBP-IA u on BMDCs and its typical MHC class II-specific up-regulation after LPS activation.
Activation of Tg4 T cells by bone marrow-derived dendritic cells from transgenic mice
To test whether the transgenes were functionally expressed and that the MBP peptide was presented by the transgenic I-A u molecules, we tested the stimulatory capacity of LPSactivated BMDCs from MBP-IA u 35 mice. Due to the high precursor frequency of MBP-specific CD4 + T cells in Tg4 mice, no prior immunization was necessary (24) and therefore we used naive purified Tg4 T cells. We titrated the cell number of transgenic BMDCs in comparison to non-transgenic and peptide-pulsed BMDCs from B10.PL mice. The transgenic BMDCs (H-2 dxb background) were highly stimulatory for Tg4 T cells, similar to peptide-pulsed BMDCs from B10.PL mice (Fig. 2C ). An allogeneic reaction can be ruled out since the MHC-matched non-transgenic BMDCs did not activate Tg4 T cells at all. This data, together with the following, show that the MBP 1-10 peptide in the transgenic mice is presented in a functional and stimulatory manner on the cell surface. Because no antibody is available for the specific MBP-IA u combination, we were not able to show the extent to which the transgenic I-A u molecules are loaded with the covalently bound MBP peptide.
Thymic deletion in double transgenic mice
As the expression of the transgenes should influence thymic selection, we crossed the transgenic lines with Tg4 mice and analyzed the thymi of F1 littermates. The crosses with MBP-IA u mice had an enormous effect on thymus size (not shown), cellularity (Table 1 ) and on selection of CD4 + thymocytes expressing the transgenic Vb8.2 chain (Fig. 3) . We found a reduction of cellularity from about 54-150 3 10 6 in Tg4 mice to 0.8-6.7 3 10 6 in Tg4 3 MBP-IA Fig. 3B ), which correlates well with the different expression levels of the transgenes. The FACS staining in Fig. 3(B) shows a high proportion of single positive (CD4 + CD8 ÿ ) in thymi from double transgenic mice. But due to the strong reduction in thymic cellularity (see legend) the absolute amount of these cells is very low. Additionally we found that expression of the transgenic Vb8.2 chain in these single-positive (CD4 + CD8 ÿ ) thymocytes of double transgenic mice was very low in comparison to thymocytes from Tg4 mice (Fig. 3B , blue events of region 3). Cells with high-expression of Vb8.2 were instead found in the double-negative thymocyte population. Figure 3(C) shows that independent of the stage of deletion, both doublepositive (CD4 + CD8 + ) and single-positive (CD4 + CD8 ÿ ) thymocytes with high expression of the transgenic Vb8.2 chain were predominantly deleted. These data show that the transgenic MBP-IA u constructs in both transgenic lines are functionally expressed in the thymus and induce strong central tolerance.
Peripheral CD4 T cells of double transgenic mice express activation markers
Despite the strong thymic-negative selection we found residual CD4 + T cells in double transgenic mice accounting for 3-14% in lymph the nodes in comparison to 30-50% in Tg4 mice (Table 1 and Fig. 4A ). Most of these cells had a downregulated Vb8.2 chain and expressed a series of activation markers (Fig. 4) . Since allelic exclusion is known to be incomplete for the TCR a chain (39, 40) and it was shown that the expression of secondary Va chains might rescue thymocytes from negative selection (41), we speculated whether this also was the case for our residual T cells in the double transgenic mice. Thymocytes from the respective mouse lines of individual animals with the indicated ages were prepared, counted and stained against CD4, CD8 and Vb8. (Fig. 4C and D) . It was recently shown that expression of antigens in the thymus induces antigen-specific regulatory CD25 + CD4 + T cells (42) . Fig. 4C and D) mice may indicate the presence of a high percentage of regulatory T cells.
Peripheral T cells of double transgenic mice are refractory to in vitro stimulation
We tested in vitro whether the residual T cells of double transgenic mice could be stimulated with the MBP peptide (Fig. 5) . We found that T cells from double transgenic mice of both transgenic lines were completely tolerant to in vitro stimulation either against the natural MBP Ac1-10 or against the higher stimulatory MBP Ac1-10 (4Y) peptide. To show that this tolerance was independent of APCs and of the reduced CD4 + T cell number in double transgenic animals, we stimulated an equal number of CD4 + T cells from Tg4 or Tg4 3 MBP-IA (Fig. 5C) . Although a decrease of proliferation was found, the low percentages of 3.3 and 1.3% displayed clear proliferative responses in comparison to the non-reactive B10.PL cells. These experiments exclude that the lack of response by double transgenic splenocytes is due to the low number of residual CD4 + F23.1 + cells. This shows that the peripheral Tcell population of double transgenic mice is in vitro tolerant against stimulation by the cognate peptide. We assume that central and peripheral tolerance mechanisms account for this unresponsiveness.
Single transgenic MBP-IA u mice are tolerant to EAE induction
To study whether expression of the transgenic MBP peptide could also influence the wild-type T cell repertoire in non-TCRtransgenic mice, we crossed the transgenic MBP-IA u lines with B10.PL mice and induced active EAE in F1-heterozygotic animals ( Table 2 , experiment 1). We found that single transgenic MBP-IA u 35 mice were almost completely tolerant towards EAE induction and five out of eight MBP-IA u 39 mice developed mild signs of EAE, whereas most of the non-transgenic littermates were highly susceptible to EAE. The onset of EAE in MBP-IA u 39 mice was very variable ranging from day 18 to 83 post-immunization. EAE duration in these mice was limited to about 3-4 days in comparison to about 10 days or chronicity in non-transgenic littermates (data not shown). These data also show that a diverse wild-type repertoire is tolerized by the transgenic MBP-IA u expression. The slightly higher EAE susceptibility of MBP-IA u 39 mice correlates well with the lower transgene expression found in these mice ( Fig. 2A) .
Peripheral T cells of double transgenic mice show regulatory capacity
To find out if a regulatory mechanism contributes to the tolerance induction by the presented antigen in vivo we ability than the CD4 + CD25 + T cells and nearly completely abolished disease induction (Fig. 6 and Table 2 ).
Late onset of EAE in double transgenic Tg4 3 MBP-IA u mice
Because of the complete in vitro unresponsiveness of double transgenic mice towards peptide stimulation and the regulatory potential of the transgenic T cells, we also expected these mice to be in vivo tolerant against EAE induction. When we induced EAE in double transgenic Tg4 3 MBP-IA u 35 mice, one out of seven mice showed an EAE score of 3 and two had symptoms of a score 1 ( Table 2 , experiment 3). When we induced active EAE in Tg4 3 MBP-IA u 39 mice, for the first 40 days they seemed to be nearly completely tolerant. Thereafter three out of four mice surprisingly developed severe signs of EAE with a clinical score of 4 at a very late onset time point (day 44-83 post-immunization) ( Table 2 ). Here also the onset varied considerably but the duration of EAE in the diseased mice lasted from about 10 days to chronicity. All single transgenic Tg4 littermates developed fulminant EAE with the typical early onset described for the Tg4-TCR-transgenic animals (32). As we wanted to know whether there was a complete loss of tolerance in diseased Tg4 3 MBP-IA u 39 mice, we tested the in vitro reactivity of splenocytes from these mice at the end of the EAE experiment (day 106 postimmunization). We did not find a complete loss of in vitro tolerance but rather a very slight reactivity of splenocytes from the two diseased mice at this time point towards Ac1-10 (4Y) (Fig. 7) . Therefore we think that the high precursor frequency in Tg4 3 MBP-IA u 39 and the continued stimulation with the peptide-CFA depot might facilitate the escape of encephalitogenic T cells from tolerance-maintaining mechanisms to develop severe EAE.
Discussion
We wanted to investigate the influence of a dominantly presented autoantigen on the susceptibility to EAE. We Similar to us, Vowles et al. expressed the autoantigenic MBP peptide 84-105 under the control of the MHC class II Ea promoter in transgenic SJL mice. As in our single transgenic mice, their transgene also had a profound effect on susceptibility to EAE induced with the MBP peptide (43) . As this group did not use TCR-transgenic mice we cannot compare our findings with double transgenic mice to their data. Another group created recombinant adenoviruses expressing MBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] bound to I-A u . The infection with adenoviruses co-expressing these constructs and B7 led to the in vitro activation of the MBP-specific hybridoma 1934.4 and to the in vivo activation of T cells in B10.PL and Pl/J mice (44) . This group did not further investigate the influence of such an infection on EAE induction or on thymic selection.
For many potential CNS autoantigens such as MBP, PLP, MOG, aB-crystallin and S100b, expression outside the CNS, in the periphery or in thymus, has been described (18-23, 45, 46) . Therefore the view of autoantigens sequestered for the naive immune system must be reconsidered at least for most putative autoantigens. The susceptibility to EAE induced by several different autoantigens or autoantigenic peptides was often explained by ''holes'' in the tolerance-inducing system. For example susceptibility to EAE in SJL/J mice, induced by PLP, was explained by the absence of thymic expression of its dominant encephalitogenic epitope (20) . Another example is the susceptibility of H-2 u -positive mice to EAE induced by MBP Ac1-9. It was shown that this peptide especially had a very low affinity to I-A u (36, 47, 48) . This was recently explained by the crystal structure of MBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] bound to I-A u showing that Ac1-11 binds in an unusual manner to I-A u occupying with only seven residues one end of the peptide groove. Also unusually the fourth residue P4 lysine was shown to bind in an unfavorable manner into the P6 pocket of I-A u (35) . Intraperitoneal injections of peptide analogs with higher affinity to I-A u , for example Ac1-9 (4Y), led to thymic deletion of MBP-specific T cells in TCR-transgenic Tg3 mice, whereas injection of the wild-type peptide led only to limited deletion in the second TCR-transgenic strain Tg4, which expressed the transgene at higher levels than the Tg3 mice (24) . This indicated that encephalitogenic T cells in H-2 u mice escape from central tolerance induction due to the sub-optimal thymic presentation of the low-affinity peptide, leading to low avidity interactions below the threshold of negative selection (24) . Recently Seamons et al. (49) showed that most MBP peptides that are presented by MBP-pulsed splenocytes from B10.PL mice are Ac1-17 or Ac1-18. The explanation for the apparent lack of tolerance against Ac1-11 in these mice was the occurrence of a second high-affinity binding register MBP5-11 with a dissociation half-life of more than 1000 h. This would compete with the binding of the low-affinity Ac1-11-register to I-A u thereby allowing release of Ac1-11-specific T cells from the thymus. In our system the transgenic expression and presentation of this low-affinity peptide covalently bound to I-A u should increase the average avidity to Ac1-10-specific thymocytes and T cells. Complementing the data from Liu et al. (24) we found massive thymic deletion in double transgenic mice of both lines (Table 1) . This shows that even in our strain with lower transgene expression, MBP-IA u 39 , in the invariant chain wild-type background, in which replacement of a big part of MHC class II covalent bound peptides has been shown (34), the efficiency of antigen presentation is considerably higher than that found after an intraperitoneal injection of the peptide.
Despite the strong thymic deletion we still found CD4 + cells expressing the transgenic Vb8.2 chain in the periphery of double transgenic animals. These cells were reduced in number and expressed a series of activation markers, which are typical signs of previous antigen contact. Staining with an antibody against the non-transgenic Va2 chain indicated that many of the escaped CD4 + Vb8. indicate that a big part of these cells have escaped thymicnegative selection via expression of endogenous TCR Va chains. This result confirms the finding by others who showed that the cortical thymic expression of an ovalbumin peptide led to receptor editing in mice also transgenic for a TCR specific for this antigen (OT-1) (41) . But in contrast to our system, they only found very limited thymic deletion in double transgenic animals.
Jordan et al. (42) have shown that the transgenic expression of an antigen in the thymus induced antigen-specific CD25-positive regulatory T cells (T reg ). Others have described the generation of T reg s of a predominant CD25-negative phenotype (50) . We found many of the residual CD4 + T cells in double transgenic mice to express CD25. But both CD4 + CD25 + and CD4 + CD25 ÿ T cells were able to regulate disease severity, the latter even with the greater potential. In our system of thymic and peripheral autoantigen expression, we did not differentiate to what extent these regulatory T cells are thymus-derived or induced in the peripheral lymphoid organs, but we describe here their generation in coexistence with the recessive tolerance mechanism of deletion.
The question arises whether normal organ-specific autoimmune diseases in humans are always the result of the previously mentioned ''holes'' in the tolerance-maintaining system or rather the result of a loss or the breaking of pre-existing tolerance mechanisms. In most animal systems only short-term experiments lasting maximal several months are performed, whereas the time span in humans from ongoing stimulation until the first signs of autoimmunity is not known.
Our results indicate that pre-existing tolerance, which includes the dominant setup of regulatory T cells, may be lost with time in situations with an elevated frequency of specific T cells and an ongoing stimulation. In this context the outbreak of autoimmune disease may rather be the tilt of a balance between tolerance and autoimmunity than a lack of tolerance described for other systems (above). Our results using double transgenic mice, which succumb to EAE after an extended induction time, suggest that long-term stimulation, for example, due to persistent viral infections, may break preexisting tolerance mechanisms and lead to organ-specific autoimmune diseases like MS in humans.
